CNO Financial Group ((CNO)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CNO Financial Group’s latest earnings call struck a distinctly upbeat tone, with management emphasizing broad-based strength across earnings, sales, and capital. Executives acknowledged pockets of pressure in Medicare supplement claims, annuity flows, and alternative investments, but framed them as manageable against a backdrop of rising ROE, expanding distribution, and disciplined capital deployment.
Operating earnings surge on cleaner, stronger core performance
CNO reported Q1 2026 operating earnings of $1.05 per diluted share, up 33% from a year earlier and 42% when stripping out significant items. Management highlighted that this growth reflects both solid top-line expansion and improved profitability, reinforcing confidence that underlying earnings power is building even before any macro tailwinds.
Sales engine and agent force extend multi-year growth streak
The company logged its 15th straight quarter of sales growth and 13th consecutive quarter of producing agent growth, with producing agents up 3% and registered agents up 7%. Leaders stressed that this consistent expansion of the sales force is central to driving sustainable premium growth, deepening customer relationships, and lifting productivity over time.
New annualized premiums climb across Consumer and Worksite
Total new annualized premiums rose 11% year over year, underscoring healthy demand across the franchise. Consumer Life & Health NAP increased 9%, while Worksite Life & Health NAP jumped 22%, signaling that CNO’s dual-channel model is delivering balanced growth across both individual and employer-focused markets.
Medicare and supplemental health deliver standout volume gains
Medicare remained a powerful growth driver, with total Medicare policies sold up 24% and Medicare supplement NAP soaring 53%. Total Health NAP rose 20%, and supplemental health premiums climbed 10%, reflecting strong market demand and positioning CNO to benefit from aging demographics despite some near-term claims pressure in MedSup.
Worksite products show broad-based strength and new client wins
Worksite results were particularly robust, with life insurance sales up 56%, hospital indemnity up 121%, and accident insurance up 18%. New annualized premiums from new clients surged 65%, driven by geographic expansion and deeper penetration, which management framed as a key vector for long-term, employer-based growth.
Annuity and brokerage assets push higher despite sales dip
Annuity account values grew 7% year over year, even as collected annuity premiums slipped 2% to $434 million against tough prior-year comparisons. Brokerage client assets rose 27% to a record level and total accounts increased 13%, bringing combined client assets and annuity account values above $18 billion, up 12% overall.
Investment income momentum backed by disciplined portfolio moves
Net investment income increased 6% year over year, marking the tenth straight quarter of growth and reflecting a larger, higher-yielding portfolio. The company deployed about $1.3 billion into new investments with an average five-year duration, while net insurance liabilities and related assets rose 4.8% and new-money yields stayed above 6% for the thirteenth consecutive quarter.
Capital returns boosted as balance sheet stays within targets
CNO returned $77 million to shareholders in the quarter, including $60 million of share repurchases that cut the weighted-average diluted share count by 7%. Book value per diluted share excluding AOCI climbed 5% to $38.98, and management noted that consolidated RBC, holding-company liquidity of $280 million, and a 26.4% debt-to-capital ratio all sit comfortably within stated targets.
Expense discipline supports margins with leverage still ahead
The expense ratio came in at 18.9%, benefiting from lower-than-planned spending in the quarter. Management cautioned that expenses should normalize over the rest of the year but expects operating leverage from growth to help keep efficiency trending favorably, rather than relying on one-off cost cuts.
Technology and AI investments begin to lift productivity
Executives pointed to ongoing investments in technology, data, and AI as a growing contributor to productivity and customer experience. Early pilots at Colonial Penn’s call centers are showing shorter wait times and better-quality sales conversions, suggesting that digital tools could unlock further revenue growth and cost efficiencies over time.
Return on equity exceeds waypoint, raising long-term ambitions
Trailing 12-month operating ROE reached 13.1%, or 12.2% excluding significant items, topping the company’s three-year 12% waypoint. Management indicated that this outperformance supports raising long-term ROE targets for 2027, though any formal update will come next year once macro conditions and capital deployment plans are clearer.
Medicare supplement claims pressure addressed with rate actions
Medicare supplement results showed modestly adverse claims experience, tempering the otherwise strong Medicare growth story. To respond, CNO has implemented and filed rate increases across closed and open blocks, with the full financial impact expected to be visible by Q4 2026, helping to restore margins in this important line.
Annuity sales volatility and alternatives weigh modestly on results
Annuity collected premiums fell 2% year over year amid tough comparisons, underscoring that flows can be choppy even as overall account values continue to grow. Alternative investment income improved versus last year but landed slightly below management’s expectations, representing a minor drag rather than a structural concern.
Market volatility and FABN spreads create temporary capital noise
Management noted that equity market weakness, with the S&P down about 5% in the quarter, reduced statutory surplus and RBC through mark-to-market impacts on FIA and interest-sensitive life reserves and related options. In addition, a less favorable spread environment for funding agreements limited arbitrage opportunities and delayed potential FABN transactions until pricing improves.
Cautious guidance stance despite strong start to the year
Looking ahead, CNO reaffirmed its original 2026 guidance, choosing not to raise targets after a strong Q1 given ongoing macro uncertainty and three quarters still to report. Executives emphasized that capital and liquidity remain solid, investment income continues to grow, MedSup rate actions should largely be in place by late 2026, and ROE targets are likely to move higher for 2027 as visibility improves.
CNO’s earnings call painted a picture of a franchise gaining earnings power, expanding distribution, and returning significant capital while keeping risk in check. While management flagged manageable headwinds in Medicare claims, annuities, and capital markets, the overall message was one of steady execution and rising confidence that ROE and shareholder returns can march higher in the coming years.